Robert Shenkar to Humans
This is a "connection" page, showing publications Robert Shenkar has written about Humans.
Connection Strength
0.394
-
mTORC1 Inhibitor Rapamycin Inhibits Growth of Cerebral Cavernous Malformation in Adult Mice. Stroke. 2023 11; 54(11):2906-2917.
Score: 0.031
-
Credulity of exploratory trials for cerebral cavernous malformations. Lancet Neurol. 2023 01; 22(1):2-3.
Score: 0.029
-
Propranolol as therapy for cerebral cavernous malformations: a cautionary note. J Transl Med. 2022 04 05; 20(1):160.
Score: 0.028
-
Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations. Genet Med. 2015 Mar; 17(3):188-196.
Score: 0.017
-
Advanced magnetic resonance imaging of cerebral cavernous malformations: part I. High-field imaging of excised human lesions. Neurosurgery. 2008 Oct; 63(4):782-9; discussion 789.
Score: 0.011
-
Concepts and hypotheses: inflammatory hypothesis in the pathogenesis of cerebral cavernous malformations. Neurosurgery. 2007 Oct; 61(4):693-702; discussion 702-3.
Score: 0.010
-
Variations in structural protein expression and endothelial cell proliferation in relation to clinical manifestations of cerebral cavernous malformations. Neurosurgery. 2005 Feb; 56(2):343-54.
Score: 0.009
-
Transcriptomic signatures of individual cell types in cerebral cavernous malformation. Cell Commun Signal. 2024 01 09; 22(1):23.
Score: 0.008
-
Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial Modeling. Stroke. 2024 01; 55(1):31-39.
Score: 0.008
-
Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part I: Event Rates and Clinical Outcome. Stroke. 2024 01; 55(1):22-30.
Score: 0.008
-
Impact of socioeconomics and race on clinical follow-up and trial enrollment and adherence in cerebral cavernous malformation. J Stroke Cerebrovasc Dis. 2023 Jul; 32(7):107167.
Score: 0.008
-
Multidisciplinary coordinated care of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease). Vasc Med. 2023 04; 28(2):153-165.
Score: 0.008
-
Differential gene expression in human cerebrovascular malformations. Neurosurgery. 2003 Feb; 52(2):465-77; discussion 477-8.
Score: 0.007
-
ß1 integrin monoclonal antibody treatment ameliorates cerebral cavernous malformations. FASEB J. 2022 12; 36(12):e22629.
Score: 0.007
-
Circulating Plasma miRNA Homologs in Mice and Humans Reflect Familial Cerebral Cavernous Malformation Disease. Transl Stroke Res. 2023 08; 14(4):513-529.
Score: 0.007
-
Perfusion and Permeability MRI Predicts Future Cavernous Angioma Hemorrhage and Growth. J Magn Reson Imaging. 2022 05; 55(5):1440-1449.
Score: 0.007
-
COVID-19 in a Hemorrhagic Neurovascular Disease, Cerebral Cavernous Malformation. J Stroke Cerebrovasc Dis. 2021 Nov; 30(11):106101.
Score: 0.007
-
Astrocytes propel neurovascular dysfunction during cerebral cavernous malformation lesion formation. J Clin Invest. 2021 07 01; 131(13).
Score: 0.007
-
Perfusion and permeability as diagnostic biomarkers of cavernous angioma with symptomatic hemorrhage. J Cereb Blood Flow Metab. 2021 11; 41(11):2944-2956.
Score: 0.007
-
PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism. Nature. 2021 06; 594(7862):271-276.
Score: 0.007
-
A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH). Neurosurgery. 2021 02 16; 88(3):686-697.
Score: 0.007
-
Common transcriptome, plasma molecules, and imaging signatures in the aging brain and a Mendelian neurovascular disease, cerebral cavernous malformation. Geroscience. 2020 10; 42(5):1351-1363.
Score: 0.006
-
Permissive microbiome characterizes human subjects with a neurovascular disease cavernous angioma. Nat Commun. 2020 05 27; 11(1):2659.
Score: 0.006
-
Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu. J Autoimmun. 2020 09; 113:102469.
Score: 0.006
-
Subclinical imaging changes in cerebral cavernous angiomas during prospective surveillance. J Neurosurg. 2020 Apr 03; 134(3):1147-1154.
Score: 0.006
-
Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. Neurosurgery. 2019 12 01; 85(6):843-853.
Score: 0.006
-
Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation. Sci Transl Med. 2019 11 27; 11(520).
Score: 0.006
-
Biology of vascular malformations of the brain. Stroke. 2009 Dec; 40(12):e694-702.
Score: 0.006
-
Biomarkers of cavernous angioma with symptomatic hemorrhage. JCI Insight. 2019 06 20; 4(12).
Score: 0.006
-
Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH). Neurosurgery. 2019 04 01; 84(4):954-964.
Score: 0.006
-
Phenotypic characterization of murine models of cerebral cavernous malformations. Lab Invest. 2019 03; 99(3):319-330.
Score: 0.005
-
Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth. Circ Res. 2018 06 08; 122(12):1716-1721.
Score: 0.005
-
Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations. J Exp Med. 2017 Nov 06; 214(11):3331-3346.
Score: 0.005
-
Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations. Transl Stroke Res. 2018 02; 9(1):34-43.
Score: 0.005
-
Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage. J Magn Reson Imaging. 2018 04; 47(4):1133-1138.
Score: 0.005
-
Endothelial TLR4 and the microbiome drive cerebral cavernous malformations. Nature. 2017 05 18; 545(7654):305-310.
Score: 0.005
-
The mutation rate of the human mtDNA deletion mtDNA4977. Am J Hum Genet. 1996 Oct; 59(4):772-80.
Score: 0.005
-
Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations. J Neurosurg. 2017 Jul; 127(1):102-110.
Score: 0.005
-
Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling. Nature. 2016 Apr 07; 532(7597):122-6.
Score: 0.005
-
Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease. Biomark Med. 2016; 10(3):255-64.
Score: 0.005
-
Vascular permeability in cerebral cavernous malformations. J Cereb Blood Flow Metab. 2015 Oct; 35(10):1632-9.
Score: 0.004
-
Evaluation of iron content in human cerebral cavernous malformation using quantitative susceptibility mapping. Invest Radiol. 2014 Jul; 49(7):498-504.
Score: 0.004
-
Immune complex formation and in situ B-cell clonal expansion in human cerebral cavernous malformations. J Neuroimmunol. 2014 Jul 15; 272(1-2):67-75.
Score: 0.004
-
Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the CCM genes: evidence for a common biochemical pathway for CCM pathogenesis. Hum Mol Genet. 2014 Aug 15; 23(16):4357-70.
Score: 0.004
-
Dynamic permeability and quantitative susceptibility: related imaging biomarkers in cerebral cavernous malformations. Stroke. 2014 Feb; 45(2):598-601.
Score: 0.004
-
A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease. Hum Mol Genet. 2011 Jan 15; 20(2):211-22.
Score: 0.003
-
Cerebral cavernous malformations as a disease of vascular permeability: from bench to bedside with caution. Neurosurg Focus. 2010 Sep; 29(3):E4.
Score: 0.003
-
Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. J Exp Med. 2010 Apr 12; 207(4):881-96.
Score: 0.003
-
Cerebral cavernous malformations: somatic mutations in vascular endothelial cells. Neurosurgery. 2009 Jul; 65(1):138-44; discussion 144-5.
Score: 0.003
-
Immune response in human cerebral cavernous malformations. Stroke. 2009 May; 40(5):1659-65.
Score: 0.003
-
Genomics of human intracranial aneurysm wall. Stroke. 2009 Apr; 40(4):1252-61.
Score: 0.003
-
Oligoclonal immune response in cerebral cavernous malformations. Laboratory investigation. J Neurosurg. 2007 Nov; 107(5):1023-6.
Score: 0.003
-
Cerebral cavernous malformations: clinical insights from genetic studies. Neurosurg Focus. 2006 Jul 15; 21(1):e1.
Score: 0.002
-
Biallelic somatic and germ line CCM1 truncating mutations in a cerebral cavernous malformation lesion. Stroke. 2005 Apr; 36(4):872-4.
Score: 0.002
-
Pathobiology of human cerebrovascular malformations: basic mechanisms and clinical relevance. Neurosurgery. 2004 Jul; 55(1):1-16; discussion 16-7.
Score: 0.002
-
On-pump coronary artery bypass surgery activates human myocardial NF-kappaB and increases TNF-alpha in the heart. J Surg Res. 2003 Jun 15; 112(2):175-9.
Score: 0.002
-
NF-kappaB regulatory mechanisms in alveolar macrophages from patients with acute respiratory distress syndrome. Shock. 2000 Feb; 13(2):85-91.
Score: 0.002
-
Nuclear factor-kappa B is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit Care Med. 1996 Aug; 24(8):1285-92.
Score: 0.001
-
Phosphatidic acid signaling mediates lung cytokine expression and lung inflammatory injury after hemorrhage in mice. J Exp Med. 1995 Feb 01; 181(2):569-75.
Score: 0.001